ONP Has Actual-Use Trial Panel, Rx-To-OTC Switch MaPP In Mind – Ganley
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Nonprescription Products may examine issues surrounding actual-use trials for OTC drugs at an advisory committee meeting later this year
You may also be interested in...
FDA Sets Outcomes Benchmarks For Actual Use Trials
FDA is providing OTC switch application sponsors with pre-defined benchmarks for actual use trials, Center for Drug Evaluation and Research executive Andrea Leonard-Segal says
ONP’s Revised MaPP Routes Steps For Investigational New Drug Applications
FDA's Office of Nonprescription Products outlines oversight and workflow procedures for filing investigational new drug applications in a newly issued Manual of Policies and Procedures released by the Center for Drug Evaluation and Research
FDA Urges More Switch Sponsor Efforts At Pre-Clinical Stage
Firms submitting switch applications should put more focus on pre-clinical testing, according to Dr. Andrea Leonard-Segal, director of the Division of Nonprescription Clinical Evaluation in FDA's Center for Drug Evaluation and Research